Zhang, Xu Dong - University of Newcastle - School of Biomedical Sciences and Pharmacy

个人简介

For more than 15 years, Dr Xu Dong Zhang has focused on translational melanoma research with an overall aim to overcome resistance of metastatic melanoma to treatment. He is currently a Professor heading the Melanoma Research Laboratory (Oncology and Immunology Unit) of the University of Newcastle (UoN)/Calvary Mater Newcastle Hospital (CMN) that consists of 3 postdoctoral researchers, 2 research assistants, 2 visiting academics, 6 PhD students, 1 laboratory manager, 1 technical officer, and 1 administrative officer. Professor Zhang has published more than 80 manuscripts in his research career. The H Factor (Index) of his publications is currently 31. In addition, He has presented my work in a large number of international and national conferences and institutional seminars, with many attendances as an invited speaker. As a chief investigator, He has attracted a large sum of funding for his research. In the past 3 years since, he was awarded an NHMRC Senior Research Fellowship (2011), and successfully renewed, for the third consecutive time, a Cancer Institute NSW (CINSW) Fellowship (2011) that is now awarded in the form of a top-up to the NHMRC Fellowship. He is a chief investigator of a translational melanoma research program grant awarded in 2011 by CINSW, and, as Chief investigator A, he has received 2 NHMRC project grants and 4 Cancer Council NSW project grants since 2009. In addition, He is a co-chief investigator of another NHMRC project grant and a chief investigator of a number of competitive grants from other funding bodies. Professor Zhang’s research has drawn considerable attention in the cancer research community worldwide and his contribution to melanoma research is highly regarded nationally and internationally. He regularly review manuscripts for high impact journals including Cancer Research and Oncogene, and assess grant applications for international and national funding bodies, such as Medical Research Council UK and NHMRC. He was a Grant Review Panel (GRP) member of NHMRC in 2011 and a a panel member of Cancer Australia in 2013. His research has also drawn extensive attention from the general public, with the highlight being 8 interviews by media including the ABC in the past 3 years. His research excellence has enabled me to establish productive collaborations with other researchers, both within academia and commercial organizations. In addition, I provide regular scientific consultancies not only locally and nationally, but also to cancer researchers of a number of highly ranked universities and institutes in China. He has proven himself to be highly competent in supervision of research high degree students and junior researchers. Since he received my first conjoint appointment in 2005 from the University of Newcastle, two PhD students have completed their studies in excellent fashion under my supervision. During the past 3 years, two postdoctoral researchers have successfully obtained NHMRC Postdoctoral Training Fellowship under his supervision. At the current time, he is the principal supervisor of 5 PhD candidates, and a co-supervisor of another two. Professor Zhang is a Co-Director of the Priority Research Centre (PRC) for Cancer of the Faulty of Health, and a Deputy Director of the Cancer Program of Hunter Medical Research Institute. He is also a member of various scientific and administering committees, including the HMRI Research Council, the Research Council of Hunter Translational Cancer Research Unit, and the Analytical and Biomolecular Research Facility Advisory Group of University of Newcastle.

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

2016 Chen J, Jiang CC, Jin L, Zhang XD, 'Regulation of PD-L1: A novel role of pro-survival signalling in cancer', Annals of Oncology, 27 409-416 (2016) [C1] 2016 Sutton SK, Carter DR, Kim P, Tan O, Arndt GM, Zhang XD, et al., 'A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner.', Oncotarget, (2016) 2016 Wang CY, Guo ST, Wang JY, Liu F, Zhang YY, Yari H, et al., 'Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress.', Mol Cancer Ther, 15 448-459 (2016) 2016 Yang RH, Tian RF, Ren QL, Chui HY, Guo ST, Zhang XD, Song X, 'Serum protein profiles of patients with lung cancer of different histological types', Asia-Pacific Journal of Clinical Oncology, 12 70-76 (2016) 2016 Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, et al., 'Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).', Autophagy, 12 1-222 (2016) 2016 Jin L, Chen J, Liu XY, Jiang CC, Zhang XD, 'The double life of RIPK1.', Mol Cell Oncol, 3 e1035690 (2016) 2016 Wang JY, Jin L, Yan XG, Sherwin S, Farrelly M, Zhang YY, et al., 'Reactive Oxygen Species Dictate the Apoptotic Response of Melanoma Cells toÂ¿TH588.', J Invest Dermatol, (2016) 2016 Wang CY, Guo ST, Wang JY, Yan XG, Farrelly M, Zhang YY, et al., 'Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922.', Oncotarget, (2016) 2016 Guo ST, Chi MN, Yang RH, Guo XY, Zan LK, Wang CY, et al., 'INPP4B is an oncogenic regulator in human colon cancer.', Oncogene, 35 3049-3061 (2016) 2016 Ye Y, Ge YM, Xiao MM, Guo LM, Li Q, Hao JQ, et al., 'Suppression of SHIP2 contributes to tumorigenesis and proliferation of gastric cancer cells via activation of Akt', Journal of Gastroenterology, 51 230-240 (2016) [C1] 2016 Meng XX, Xu HX, Yao M, Dong Q, Zhang XD, 'Implication of Unfolded Protein Response and Autophagy in the Treatment of BRAF Inhibitor Resistant Melanoma.', Anticancer Agents Med Chem, 16 291-298 (2016) 2015 Roselli S, Pundavela J, Demont Y, Faulkner S, Keene S, Attia J, et al., 'Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion', Oncotarget, 6 10473-10486 (2015) [C1] 2015 Tay KH, Liu X, Chi M, Jin L, Jiang CC, Guo ST, et al., 'Involvement of vacuolar H+-ATPase in killing of human melanoma cells by the sphingosine kinase analogue FTY720', Pigment Cell and Melanoma Research, 28 171-183 (2015) [C1] 2015 Luan Q, Jin L, Jiang CC, Tay KH, Lai F, Liu XY, et al., 'RIPK1 regulates survival of human melanoma cells upon endoplasmic reticulum stress through autophagy.', Autophagy, 11 975-994 (2015) [C1] 2015 Meng X-X, Yao M, Zhang XD, Xu H-X, Dong Q, 'ER stress-induced autophagy in melanoma', CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 42 811-816 (2015) [C1] 2015 Jiang C, Chi MN, Guo ST, Wilmott JS, Guo X Y, Yan X G, et al., 'INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas', Oncotarget, 6 39891-39907 (2015) [C1] 2015 Chen J, Zhang XD, Proud C, 'Dissecting the signaling pathways that mediate cancer in PTEN and LKB1 double-knockout mice', Science Signaling, 8 (2015) [C1] 2015 Liu XY, Lai F, Yan XG, Jiang CC, Guo ST, Wang CY, et al., 'RIP1 kinase is an oncogenic driver in melanoma', Cancer Research, 75 1736-1748 (2015) [C1] 2015 Zou X, Zhang M, Sun Y, Zhao S, Wei Y, Zhang X, et al., 'Inhibitory effects of 3-bromopyruvate in human nasopharyngeal carcinoma cells', ONCOLOGY REPORTS, 34 1895-1904 (2015) [C1] 2014 Liu PY, Erriquez D, Marshall GM, Tee AE, Polly P, Wong M, et al., 'Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression.', J Natl Cancer Inst, 106 (2014) [C1]